Get notified regarding key financial metrics and revenue changes at AblynxLearn more
Banner background

Summary - Funding Rounds

Founding Date

2001

Total Funding

$498.8 m

Investors

In total, Ablynx had raised $498.8 m. Ablynx is a subsidiary of Sanofi

Ablynx Income Statement

Annual

EURFY, 2015FY, 2016

Revenue

77.5m85.2m

Revenue growth, %

10%

R&D expense

83.1m100.3m

General and administrative expense

11.4m13.5m

Operating expense total

94.5m113.8m

EBIT

(17.0m)(28.6m)

EBIT margin, %

(22%)(34%)

Interest expense

39.4m7.2m

Interest income

1.8m34.8m

Pre tax profit

(54.5m)(1.1m)

Net Income

(54.5m)(1.1m)

EPS

(1.0)(0.4)

Ablynx Balance Sheet

Annual

EURFY, 2015FY, 2016

Cash

3.6m53.4m

Accounts Receivable

9.3m4.8m

Current Assets

246.1m242.2m

PP&E

2.6m3.7m

Total Assets

265.3m266.8m

Accounts Payable

16.4m25.7m

Current Liabilities

102.5m59.4m

Non-Current Liabilities

134.8m104.3m

Common Stock

96.3m106.1m

Additional Paid-in Capital

187.3m252.3m

Retained Earnings

(262.3m)(263.4m)

Total Equity

27.9m103.1m

Financial Leverage

9.5 x2.6 x

Quarterly

EURQ2, 2015Q2, 2016

Cash

53.4m26.4m

Accounts Receivable

4.8m4.1m

Current Assets

242.2m210.5m

PP&E

3.7m3.9m

Total Assets

266.8m235.2m

Accounts Payable

25.7m27.4m

Current Liabilities

59.4m51.5m

Non-Current Liabilities

104.3m103.3m

Common Stock

106.1m107.2m

Additional Paid-in Capital

252.3m253.3m

Retained Earnings

(263.4m)(288.7m)

Total Equity

103.1m80.4m

Financial Leverage

2.6 x2.9 x

Ablynx Cash Flow

Annual

EURFY, 2015FY, 2016

Net Income

(54.5m)(1.1m)

Depreciation and Amortization

1.1m1.8m

Accounts Receivable

11.6m(86.0k)

Accounts Payable

(45.2m)(43.2m)

Cash From Operating Activities

(69.0m)(66.6m)

Purchases of PP&E

(1.5m)(2.9m)

Cash From Investing Activities

(39.7m)45.9m

Long-term Borrowings

(141.0k)

Cash From Financing Activities

100.6m70.4m

Net Change in Cash

(8.1m)49.8m

Quarterly

EURQ2, 2016Q2, 2017

Net Income

22.8m(25.3m)

Depreciation and Amortization

885.0k1.5m

Accounts Receivable

(3.8m)(568.0k)

Accounts Payable

(21.4m)(7.9m)

Cash From Operating Activities

(17.2m)(29.3m)

Purchases of PP&E

(2.1m)(1.2m)

Cash From Investing Activities

31.6m2.5m

Cash From Financing Activities

71.9m(214.0k)

Net Change in Cash

86.3m(27.0m)

Ablynx Ratios

EURQ2, 2015

Financial Leverage

2.6 x

Ablynx Operating Metrics

Q2, 2017

Clinical Programs

45

Patents (US)

50

Patents (Foreign)

180

Patents and Patent Applications

400

Patients Reached

2 k

Ablynx Employee Rating

3.212 votes
Culture & Values
3.9
Work/Life Balance
3.4
Senior Management
2.7
Salary & Benefits
2.9
Career Opportunities
2.4
Source